美国7个中心COVID-19高峰期间1型糖尿病酮症酸中毒趋势:非西班牙裔黑人患者负担最高
该研究比较了美国7个大型医疗中心1型糖尿病(T1D)患者在COVID-19高峰1期(2020年3-5月)和高峰2期(2020年8-10月)与2019年同期的糖尿病酮症酸中毒(DKA)事件。结果显示2020年与2019年发生DKA的T1D患者绝对数无差异,但2020年高峰期间DKA患者比例高于2019年同期,非西班牙裔黑人(NHB)患者DKA比例始终高于非西班牙裔白人(NHW)患者,使用持续葡萄糖监测(CGM)或胰岛素泵的患者DKA较少见。
要点
- 2020年与2019年发生DKA的T1D患者绝对数无差异。
- NHB患者DKA比例2019年为44.6% vs NHW 16.0%(P < .001),疫情期间为48.6% vs 18.6%(P < .001)。
- 2020年使用CGM或胰岛素泵的患者DKA较少见(CGM:13.2% vs 15.0%,P < .001;胰岛素泵:8.0% vs 10.6%,P < .001)。
核心结论
- COVID-19高峰期间T1D患者DKA频率增加,NHB患者频率最高,使用CGM或胰岛素泵的患者DKA较少见。
- 作者认为这些发现突出表明迫切需要改进策略以预防T1D患者DKA,不仅在大流行条件下而且在所有条件下,尤其在受健康不公平影响最大的人群中。
研究设计与样本
- 比较美国7个大型医疗中心T1D儿童和成人在COVID-19高峰1期(2020年3-5月)和高峰2期(2020年8-10月)与2019年同期的DKA事件。
- 分析采用描述性统计和卡方检验。
主要发现
- 2019年与2020年发生DKA的T1D患者绝对数无差异。
- NHB患者DKA比例2019年为44.6% vs NHW 16.0%(P < .001),COVID-19大流行期间为48.6% vs 18.6%(P < .001)。
- 2020年使用CGM或胰岛素泵的患者DKA较少见(CGM:13.2% vs 15.0%,P < .001;胰岛素泵:8.0% vs 10.6%,P < .001)。
- 与年度DKA总数相反,COVID-19高峰1期和2期发生DKA的患者比例高于2019年同期(高峰1期:7.1% vs 5.4%,P < .001;高峰2期:6.6% vs 5.7%,P = .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The impact of the COVID-19 pandemic on individuals with type 1 diabetes remains poorly defined. OBJECTIVE: We examined United States trends in diabetic ketoacidosis (DKA) among individuals with type 1 diabetes (T1D) during the COVID-19 pandemic at 7 large US medical centers and factors associated with these trends. METHODS: We compared DKA events among children and adults with T1D during COVID-19 surge 1 (March-May 2020) and COVID-19 surge 2 (August-October 2020) to the same periods in 2019. Analysis was performed using descriptive statistics and chi-square tests. RESULTS: We found no difference in the absolute number of T1D patients experiencing DKA in 2019 vs 2020. However, a higher proportion of non-Hispanic Black (NHB) individuals experienced DKA in 2019 than non-Hispanic White (NHW) individuals (44.6% vs 16.0%; P < .001), and this disparity persisted during the COVID-19 pandemic (48.6% vs 18.6%; P < .001). DKA was less common among patients on continuous glucose monitor (CGM) or insulin pump in 2020 compared to 2019 (CGM: 13.2% vs 15.0%, P < .001; insulin pump: 8.0% vs 10.6%, P < .001). In contrast to annual DKA totals, a higher proportion of patients had DKA during COVID-19 surges 1 and 2 compared to the same months in 2019 (surge 1: 7.1% vs 5.4%, P < .001; surge 2: 6.6% vs 5.7%, P = .001). CONCLUSION: DKA frequency increased among T1D patients during COVID-19 surges with highest frequency among NHB patients. DKA was less common among patients using CGM or insulin pumps. These findings highlight the urgent need for improved strategies to prevent DKA among patients with T1D-not only under pandemic conditions, but under all conditions-especially among populations most affected by health inequities.
引用
- Lavik AR, Ebekozien O, Noor N, et al. Trends in Type 1 Diabetic Ketoacidosis During COVID-19 Surges at 7 US Centers: Highest Burden on non-Hispanic Black Patients. J Clin Endocrinol Metab. 2022. PMID: 35380700. doi:10.1210/clinem/dgac158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。